Goldline Pharmaceutical IPO GMP: Price Band, Dates, Lot Size & Complete IPO Review

The SME IPO market continues to remain active with the launch of the Goldline Pharmaceutical IPO, which has already started gaining attention among investors tracking the latest Goldline Pharmaceutical IPO GMP trends. According to Finowings, the IPO is a book-built issue worth ₹11.61 crore and consists entirely of a fresh issue of approximately 0.27 crore equity shares.

Investors in the SME segment are closely monitoring the Goldline Pharmaceutical IPO GMP because grey market activity often provides early indications about market sentiment and possible listing expectations. The pharmaceutical sector has historically attracted investor interest due to its consistent demand and long-term growth potential, making this IPO one of the notable SME issues in the healthcare segment.

The Goldline Pharmaceutical IPO opened for subscription on May 12, 2026, and will close on May 14, 2026. The IPO allotment process is expected to be finalized on May 15, 2026. Following the allotment, the shares are scheduled to be listed on the Bombay Stock Exchange SME platform with a tentative listing date of May 19, 2026.

The company has fixed the IPO price band at ₹41 to ₹43 per share. Investors planning to apply for the issue should carefully review the lot size and investment requirements before submitting their applications. The IPO comes with a lot size of 3,000 shares, which makes the minimum investment requirement relatively high compared to many mainboard IPOs.

For retail investors, the minimum application requires 2 lots, which equals 6,000 shares. Based on the upper price band of ₹43 per share, the minimum retail investment amount stands at ₹2,58,000. Meanwhile, High Net-worth Individuals (HNIs) are required to apply for a minimum of 3 lots, or 9,000 shares, amounting to an investment of approximately ₹3,87,000.

Below is a quick overview of the IPO details:

• IPO Name: Goldline Pharmaceutical IPO

• Issue Size: ₹11.61 Crore

• Issue Type: Book Build Issue

• Fresh Issue: 0.27 Crore Shares

• Price Band: ₹41 to ₹43 per share

• Lot Size: 3,000 Shares

• IPO Open Date: May 12, 2026

• IPO Close Date: May 14, 2026

• Allotment Date: May 15, 2026

• Tentative Listing Date: May 19, 2026

• Exchange: Bombay Stock Exchange SME Platform

The Goldline Pharmaceutical IPO GMP is likely to remain a major discussion point among SME investors during the subscription period. Grey Market Premium (GMP) reflects the unofficial premium at which IPO shares trade before listing. A strong GMP generally indicates positive investor sentiment, while weaker GMP trends may signal cautious market expectations. However, investors should remember that GMP is unofficial and can fluctuate significantly based on market demand, subscription levels, and overall stock market conditions.

The pharmaceutical industry in India continues to show strong long-term growth potential due to rising healthcare demand, increasing medical awareness, and expanding pharmaceutical exports. SME pharmaceutical companies entering the public market often seek capital to expand manufacturing capacity, strengthen working capital, and improve distribution networks. Investors looking at the Goldline Pharmaceutical IPO GMP may also evaluate the company’s business fundamentals, financial growth, competitive positioning, and future expansion plans before making investment decisions.

While GMP trends may provide short-term indications, long-term investment success depends on the company’s operational performance and profitability. Investors are advised to study the company’s financial statements, risk factors, valuation, and sector outlook carefully instead of relying solely on grey market activity.

For the latest updates on Goldline Pharmaceutical IPO GMP, subscription status, allotment details, and listing expectations, investors can visit:
Goldline Pharmaceutical IPO Details on Finowings